-
Political opposition from both Britain and America could derail any attempt at a deal, especially given the backdrop of the Covid-19 outbreak. The timing is also questionable, as while Gilead is in the middle of a turnaround, AstraZeneca is well positioned and has a strong pipeline, analysts said.June 8
-
Gilead’s hepatitis C franchise turned the company into a pharma industry giant, but sales of the drugs have slipped from their peak and it has struggled to find new streams of revenue.March 2
-
Call for Nominations: Deadline is Feb. 7 for M&A Mid-Market Awards. We've named the 2020 Most Influential Women. What's ahead for M&A in 2020? We ask bankers from Stifel, Piper Jaffray, William Blair. In deal news, Eli Lilly is buying skin condition treatment company Dermira.January 10
-
Gene therapy is a new area of medicine that has sparked a flurry of deals.December 3
-
Amgen buys Otezla from Celgene. Temenos acquires Kony. Pernod Ricard picks up Castle Brands.August 30
-
Antitrust authorities have taken an increasing interest in pharmaceutical deals, which have in the past attracted less scrutiny.August 27
-
Merck and Amgen are among the active dealmakers, as they look to replace expired patents through acquisitions.August 23
-
Merck, Amgen, look to replenish their drug pipelines with cancer deals. Silver Lake, GIC, pull out $900 million from Ancestry.com. Vista makes add-on acquisition for Quick Base.August 15
-
The generic-drug industry has been under increasing pressure in recent years as competition drives prices lower and lower.July 29
-
The deal diversifies AbbVie's revenue from Humira and will also return Allergan to the U.S., at least for tax purposes.June 25
